Bệnh Parkinson và nghiên cứu chuyển giao

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–7. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(1):a008888. Singleton AB, Hardy JA, Gasser T. The birth of the modern era of Parkinson’s disease genetics. J Parkinsons Dis. 2017;7(s1):S87–93. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40. Holdorff B, Rodrigues e Silva AM, Dodel R. Centenary of Lewy bodies (1912–2012). J Neural Transm. 2013;120(4):509–16. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O’Sullivan GA, Pal A, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2012;2(1):898. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117(6):613–34. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469–73. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson“s disease and Parkinson”s disease dementia. Acta Neuropathol. 2010;120(2):131–43. Doppler K, Brockmann K, Sedghi A, Wurster I, Volkmann J, Oertel WH, et al. Dermal phospho-alpha-synuclein deposition in patients with Parkinson’s disease and mutation of the glucocerebrosidase gene. Front Neurol. 2018;9:1094. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998;249(2–3):180–2. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600–11. Haehner A, Masala C, Walter S, Reichmann H, Hummel T. Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss. J Neurol. 2019;266(2):339–45. Klingelhoefer L, Reichmann H. The gut and nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:787–809. Krohn L, Wu RYJ, Heilbron K, Ruskey JA, Laurent SB, Blauwendraat C, et al. Fine-mapping of SNCA in rapid eye movement sleep behavior disorder and overt synucleinopathies. Ann Neurol. 2020;87(4):584–98. Smith C, Malek N, Grosset K, Cullen B, Gentleman S, Grosset DG. Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies. J Neurol Neurosurg Psychiatry. 2019;90(11):1234–43. Coughlin DG, Petrovitch H, White LR, Noorigian J, Masaki KH, Ross GW, et al. Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but “failure to fit” is highly dependent on staging system applied. Parkinsonism Relat Disord. 2019;64:124–31. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology. 2004;62(9):1619–22. Schulz-Schaeffer WJ. Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology. 2012;79(24):2298–9. Martinez Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406. Agerschou ED, Flagmeier P, Saridaki T, Galvagnion C, Komnig D, Heid L, et al. An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils. Elife. 2019;8:e46112. Pujols J, Peña-Díaz S, Pallarès I, Ventura S. Chemical chaperones as novel drugs for Parkinson’s disease. Trends Mol Med. 2020;26(4):408–21. Burmann BM, Gerez JA, Matečko-Burmann I, Campioni S, Kumari P, Ghosh D, et al. Regulation of α-synuclein by chaperones in mammalian cells. Nature. 2020;577(7788):127–32. Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353(6307):1513. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol. 2012;72(4):517–24. Stopschinski BE, Holmes BB, Miller GM, Manon VA, Vaquer-Alicea J, Prueitt WL, et al. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates. J Biol Chem. 2018;293(27):10826–40. Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, et al. Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology. Acta Neuropathol Comm. 2017;5(1):46. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42. Emmanouilidou E, Minakaki G, Keramioti MV, Xylaki M, Balafas E, Chrysanthou-Piterou M, et al. GABA transmission via ATP-dependent K+ channels regulates α-synuclein secretion in mouse striatum. Brain. 2016;139(Pt 3):871–90. Saridaki T, Falkenburger BH. Transport and clearance of α-synuclein aggregates. FASEB. 2014;18:1–42. Yamada K, Iwatsubo T. Extracellular α-synuclein levels are regulated by neuronal activity. Mol Neurodegener. 2018;13(1):9–8. Karpowicz RJ, Haney CM, Mihaila TS, Sandler RM, Petersson EJ, Lee VMY. Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. J Biol Chem. 2017;292(32):13482–97. Abounit S, Bousset L, Loria F, Zhu S, de Chaumont F, Pieri L, et al. Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016;35(19):2120–38. Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OMA, et al. Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. Brain. 2016;139(Pt 3):856–70. Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A, et al. Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathologica Communications. 2015;3(1):197 2nd ed. Karpinar DP, Balija MBG, Kügler S, Opazo F, Rezaei-Ghaleh N, Wender N, et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson’s disease models. EMBO J. 2009;28(20):3256–68. Prots I, Grosch J, Brazdis RM, Simmnacher K, Veber V, Havlicek S, et al. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc Natl Acad Sci U S A. 2018;115(30):7813–8. Peelaerts W, Bousset L, Baekelandt V, Melki R. ɑ-Synuclein strains and seeding in Parkinson’s disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences. Cell Tissue Res. 2018;105(20):84–18. Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273–7. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340–4. Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC, et al. α-Synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23(1):21–31. Opazo F, Krenz A, Heermann S, Schulz JB, Falkenburger BH. Accumulation and clearance of -synuclein aggregates demonstrated by time-lapse imaging. J Neurochem. 2008;106(2):529–40. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10(12):524–30. Lamark T, Johansen T. Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int J Cell Biol. 2012;2012(12):736905–21. Bersuker K, Brandeis M, Kopito RR. Protein misfolding specifies recruitment to cytoplasmic inclusion bodies. J Cell Biol. 2016;213(2):229–41. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci. 2011;31(41):14508–20. Dinter E, Saridaki T, Nippold M, Plum S, Diederichs L, Komnig D, et al. Rab7 induces clearance of α-synuclein aggregates. J Neurochem. 2016;138(5):758–74. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem. 2005;280(48):40282–92. Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, O’Kane CJ, et al. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat Genet. 2005;37(7):771–6. Liu X, Li Y, Wang X, Xing R, Liu K, Gan Q, et al. The BEACH-containing protein WDR81 coordinates p62 and LC3C to promote aggrephagy. J Cell Biol. 2017;216(5):1301–20. Saridaki T, Nippold M, Dinter E, Roos A, Diederichs L, Fensky L, et al. FYCO1 mediates clearance of α-synuclein aggregates through a Rab7-dependent mechanism. J Neurochem. 2018;146(4):474–92. Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004;3(8):496–503. McCormack A, Keating DJ, Chegeni N, Colella A, Wang JJ, Chataway T. Abundance of synaptic vesicle-related proteins in alpha-synuclein-containing protein inclusions suggests a targeted formation mechanism. Neurotox Res. 2019;35(4):883–97. Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019;22(7):1099–109. Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020;117(9):4971–82. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti–α-synuclein monoclonal antibody, in patients with Parkinson disease: A Randomized Clinical Trial. JAMA Neurol. 2018;75(10):1206–14. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron. 2005;46(6):857–68. Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci. 2014;34(28):9441–54. Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Comm. 2014;2(1):88. Wu Q, Takano H, Riddle DM, Trojanowski JQ, Coulter DA, Lee VMY. α-Synuclein (αSyn) preformed fibrils induce endogenous αSyn aggregation, compromise synaptic activity and enhance synapse loss in cultured excitatory hippocampal neurons. J Neurosci. 2019;39(26):5080–94. Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, et al. Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. Acta Neuropathol Comm. 2013;1(1):38. Musgrove RE, Helwig M, Bae EJ, Aboutalebi H, Lee SJ, Ulusoy A, et al. Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. J Clin Invest. 2019;129(9):3738–53. Crabbé M, Van der Perren A, Kounelis S, Lavreys T, Bormans G, Baekelandt V, et al. Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced α-synucleinopathy. Exp Neurol. 2019;320:112964. Volpicelli-Daley LA, Luk KC, Lee VMY. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc. 2014;9(9):2135–46. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75(3):351–62. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchère J, Lakhdar L, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33(9):2225–8. Brundin P, Melki R. Prying into the prion hypothesis for Parkinson’s disease. J Neurosci. 2017;37(41):9808–18. Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Boeve BF, Sletten DM, et al. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies. Ann Neurol. 2020. https://doi.org/10.1002/ana.25824. Tsukita K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, Takahashi R. Value of in vivo α-synuclein deposits in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2019;34(10):1452–63. Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32(9):1264–310. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):337–41. Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement. Mov Disord. 2014;29(14):1710–9. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290(5493):985–9. Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science. 2017;357(6357):1255–61. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003;179(1):9–16. Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nature. 2015;11(11):625–36. Mahlknecht P, Gasperi A, Djamshidian A, Kiechl S, Stockner H, Willeit P, et al. Performance of the Movement Disorders Society criteria for prodromal Parkinson’s disease: A population-based 10-year study. Mov Disord. 2018;33(3):405–13. Butler B, Sambo D, Khoshbouei H. Alpha-synuclein modulates dopamine neurotransmission. J Chem Neuroanat. 2017;83–84:41–9. Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–53. Matsui H, Kenmochi N, Namikawa K. Age- and α-synuclein-dependent degeneration of dopamine and noradrenaline neurons in the annual killifish Nothobranchius furzeri. Cell Rep. 2019;26(7):1727–1733.e6. Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012;27(1):8–30. Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18(2):101–13. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov Disord. 2013;28(6):715–24. Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci. 2005;8(12):1742–51. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136(Pt 8):2419–31. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366–75. DeLong M, Wichmann T. Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord. 2009;15:S237–40. Wichmann T. Changing views of the pathophysiology of Parkinsonism. Mov Disord. 2019;34(8):1130–43. Hutchison WD. Neuronal oscillations in the basal ganglia and movement disorders: evidence from whole animal and human recordings. J Neurosci. 2004;24(42):9240–3. Mink JW. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol. 2003;60(10):1365–8. Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol. 2010;6(9):487–98. Moll CKE, Engel AK. Phase matters: cancelling pathological tremor by adaptive deep brain stimulation. Brain. 2017;140(1):5–8. Holt AB, Kormann E, Gulberti A, Pötter Nerger M, McNamara CG, Cagnan H, et al. Phase-dependent suppression of beta oscillations in Parkinson’s disease patients. J Neurosci. 2019;39(6):1119–34. Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res. 1989;503(2):334–8. Fieblinger T, Graves SM, Sebel LE, Alcacer C, Plotkin JL, Gertler TS, et al. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun. 2014;5(1):5316. Suarez LM, Alberquilla S, García-Montes JR, Moratalla R. Differential synaptic remodeling by dopamine in direct and indirect striatal projection neurons in Pitx3−/− mice, a genetic model of Parkinson’s disease. J Neurosci. 2018;38(15):3619–30. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, et al. Evidence of a breakdown of corticostriatal connections in Parkinson’s disease. Neuroscience. 2005;132(3):741–54. Ali Z, Roque A, El-Mallakh RS. A unifying theory for the pathoetiologic mechanism of tardive dyskinesia. Med Hypotheses. 2020;140:109682. Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol. 1997;42(3):349–55. Stocchi F, Vacca L, Berardelli A, De Pandis F, Ruggieri S. Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov Disord. 2001;16(2):301–5. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. New Eng J Med. 2004;351(24):2498–508. Schultz W. Recent advances in understanding the role of phasic dopamine activity. F1000Res. 2019;8(1680):1680. Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B. Levodopa-induced plasticity: a double-edged sword in Parkinson’s disease? Phil Trans R Soc B. 2015;370(1672):20140184. Tyssowski KM, Letai KC, Rendall SD, Tan C, Nizhnik A, Kaeser PS, et al. Firing rate homeostasis can occur in the absence of neuronal activity-regulated transcription. J Neurosci. 2019;39(50):9885–99. Tanimura A, Du Y, Kondapalli J, Wokosin DL, Surmeier DJ. Cholinergic interneurons amplify thalamostriatal excitation of striatal indirect pathway neurons in Parkinson’s disease models. Neuron. 2019;101(3):444–6. Moehle MS, Conn PJ. Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders. Mov Disord. 2019;34(8):1089–99. Fernández-Dueñas V, Ferré S, Ciruela F. Adenosine A2A-dopamine D2 receptor heteromers operate striatal function: impact on Parkinson’s disease pharmacotherapeutics. Neural Regen Res. 2018;13(2):241–3.